

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

# FIG. 1

SAHA Patient: IV vs ORAL (200 mg/dose)

Patient #

Week 1      Week 2

1-OS-200

- +  
Marker  
Pre      Post  
Pre      Post-2hrs  
Post-4hrs

IV

ORAL

$\alpha$ -ACh4

Coomassie blue



# FIG. 2

Protocol 01-021 (ORAL SAHA) ARM A: SOLID TUMOR PATIENTS Cohort I (200 mg/dose)





FIG. 3



# FIG. 4

Protocol 01-021 (ORAL SAHA)  
ARM A: SOLID TUMOR PATIENTS  
Cohort I (200 mg/dose)





FIG. 5



三  
六  
九

## SAHA Patients: ORAL/Cohort II (400 mg/dose)

9-OS-400  
10-OS-400

ORAL N ORAL

2 h  
Pre  
2 h  
6 h  
Pre  
2 h  
Pre  
2 h  
8 h

卷之三

卷之三

卷之三

卷之三

卷之三

卷之三

卷之三


Coomassie  
stain

$\alpha$ -ACh3


6/19

FIG. 7

Protocol 01-021  
(ORAL SAHA)  
ARM A: SOLID  
TUMOR PATIENTS  
Cohort IIa (400 mg/dose)




三  
〇




**FIG. 9A**


Oral 200 mg vs. 400 mg (Fasting)  
Oral dose on Cycle 1 Day 8



**FIG. 9B**  
Oral 200 mg vs. 400 mg (no-fasting)  
Oral Dose on Cycle 1 Day 9




**FIG. 9C**  
IV 200 mg vs. 400 mg  
IV Dose on Cycle 1 Day 1



11/19


FIG. 10

Apparent Half-life of the Oral Dose  
Half-life



**FIG. 11**

AUC of the Oral  
Dose AUC<sub>last</sub>



**FIG. 12**

Bioavailability after 200 and 400 mg by Day





FIG. 13A

CTCL Patient 001 (MD Anderson)

Baseline

After 1 Week of SAHA



**FIG. 13B**

CTCL Patient 001 (MD Anderson)

Baseline

After 1 Week of SAHA



**FIG. 13C**

CTCL Patient (MDACC)

Baseline

After 8 weeks of SAHA




FIG. 13D

CTCL Patient 008 (MD Anderson)

Baseline

After 8 weeks of SAHA




FIG. 14

Metastatic Laryngeal Cancer (MSKCC)

Pre-treatment

After 8 weeks of treatment

